company background image
BIO3 logo

Biotest XTRA:BIO3 Stock Report

Last Price

€27.60

Market Cap

€1.4b

7D

0%

1Y

-9.8%

Updated

24 May, 2024

Data

Company Financials +

Biotest Aktiengesellschaft

XTRA:BIO3 Stock Report

Market Cap: €1.4b

BIO3 Stock Overview

Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.

BIO3 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health3/6
Dividends0/6

Biotest Aktiengesellschaft Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biotest
Historical stock prices
Current Share Price€27.60
52 Week High€33.20
52 Week Low€22.80
Beta0.24
1 Month Change-4.50%
3 Month Change-2.13%
1 Year Change-9.80%
3 Year Change-4.83%
5 Year Change24.32%
Change since IPO337.93%

Recent News & Updates

Recent updates

Shareholder Returns

BIO3DE BiotechsDE Market
7D0%-1.6%-0.5%
1Y-9.8%-24.7%5.2%

Return vs Industry: BIO3 exceeded the German Biotechs industry which returned -25.9% over the past year.

Return vs Market: BIO3 underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is BIO3's price volatile compared to industry and market?
BIO3 volatility
BIO3 Average Weekly Movement4.4%
Biotechs Industry Average Movement5.2%
Market Average Movement5.0%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market2.5%

Stable Share Price: BIO3 has not had significant price volatility in the past 3 months.

Volatility Over Time: BIO3's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19462,426Peter Janssenwww.biotest.com

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.

Biotest Aktiengesellschaft Fundamentals Summary

How do Biotest's earnings and revenue compare to its market cap?
BIO3 fundamental statistics
Market cap€1.37b
Earnings (TTM)€176.90m
Revenue (TTM)€782.60m

6.2x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIO3 income statement (TTM)
Revenue€782.60m
Cost of Revenue€436.40m
Gross Profit€346.20m
Other Expenses€169.30m
Earnings€176.90m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 30, 2024

Earnings per share (EPS)4.47
Gross Margin44.24%
Net Profit Margin22.60%
Debt/Equity Ratio131.3%

How did BIO3 perform over the long term?

See historical performance and comparison

Dividends

0.1%

Current Dividend Yield

0.9025%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.